Trial Profile
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF-06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2020
Price :
$35
*
At a glance
- Drugs Danuglipron (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 06 Jun 2019 Status changed from recruiting to completed.
- 18 Feb 2019 Planned End Date changed from 20 Apr 2019 to 17 Jun 2019.